FindTrial
Sign In

The use of colorectal cancer organoids to study the clonal origin and the molecular mechanism of drug-tolerant persister cells underlying resistance to irinotecan

The use of colorectal cancer organoids to study the clonal origin and the molecular mechanism of drug-tolerant persister cells underlying resistance to irinotecan

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115280
Enrollment
Unknown
Registered
2025-12-24
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Trial group:None

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The participant voluntarily joins the study and signs the informed consent form. 2. The age range is between 20 and 80 years old. 3. Patients diagnosed with colorectal cancer who have undergone tumor surgical resection.

Exclusion criteria

Exclusion criteria: Patients who had undergone chemotherapy treatment

Design outcomes

Primary

MeasureTime frame
Organoid generation;transcriptome sequencing;Distribution of cell subpopulations, differentially expressed signaling pathways, and key genes;—

Countries

Chine

Contacts

Public ContactLI Zhichao

Shenzhen Second People's Hospital

liz_hichao@126.com+86 150 1274 1564

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026